SNDX
Company Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 172.35M | 23.68M | 0 | 0 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627,000 | 0 |
| Net Income | (285.42M) | (318.76M) | (209.36M) | (149.34M) | 24.93M | (73.07M) | (55.95M) | (73.96M) | (60.80M) | (44.47M) | (24.12M) | (19.83M) |
| EPS | -3.29 | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -4.31 | -2.07 |
| Free Cash Flow | (323.17M) | (274.90M) | (160.60M) | (133.90M) | 29.00M | (71.26M) | (50.61M) | (68.72M) | (47.45M) | (35.42M) | N/A | N/A |
| FCF / Share | -3.73 | -3.21 | -2.28 | -2.20 | 0.56 | -1.73 | -1.66 | -2.71 | -2.26 | -2.42 | N/A | N/A |
| Operating CF | (322.98M) | (274.90M) | (160.60M) | (133.68M) | 29.13M | (71.26M) | (50.61M) | (68.53M) | (47.37M) | (35.16M) | N/A | N/A |
| Total Assets | 529.71M | 724.82M | 612.88M | 497.24M | 449.66M | 300.61M | 63.52M | 83.94M | 137.19M | 109.01M | N/A | N/A |
| Total Debt | 346.48M | 345.74M | 1.64M | 1.16M | 20.97M | 20.54M | 897,000 | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 134.93M | 154.08M | 295.39M | 74.36M | 221.97M | 115.24M | 24.61M | 33.77M | 35.17M | 23.84M | N/A | N/A |
| Book Value | 64.63M | 288.12M | 554.20M | 467.45M | 408.37M | 252.19M | 31.60M | 53.05M | 104.32M | 84.14M | N/A | N/A |
| Return on Equity | -4.42 | -1.11 | -0.38 | -0.32 | 0.06 | -0.29 | -1.77 | -1.39 | -0.58 | -0.53 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.86M | 68.48M | 45.87M | 37.96M | 20.04M | 7.68M | 12.50M | 3.50M | 0 | 0 | 0 | 0 |
| Net Income | (42.67M) | (68.01M) | (60.72M) | (71.85M) | (84.85M) | (94.17M) | (84.13M) | (68.06M) | (72.40M) | (72.47M) | (51.15M) | (44.62M) |
| EPS | -0.49 | -0.78 | -0.70 | -0.83 | -0.99 | -1.10 | -0.98 | -0.80 | -0.85 | -1.00 | -0.73 | -0.64 |
| Free Cash Flow | (50.34M) | (69.54M) | (70.67M) | (87.80M) | (95.16M) | (57.39M) | (62.32M) | (71.64M) | (83.55M) | (41.35M) | (44.65M) | (35.37M) |
| FCF / Share | -0.58 | -0.80 | -0.82 | -1.02 | -1.11 | -0.67 | -0.73 | -0.84 | -0.98 | -0.57 | -0.64 | -0.51 |
| Operating CF | (50.34M) | (69.49M) | (70.53M) | (87.80M) | (95.16M) | (57.39M) | (62.32M) | (71.64M) | (83.55M) | (41.35M) | (44.65M) | (35.37M) |
| Total Assets | 472.67M | 529.71M | 551.79M | 596.15M | 640.71M | 724.82M | 425.81M | 476.95M | 543.03M | 612.88M | 399.22M | 431.34M |
| Total Debt | 345.36M | 346.48M | 345.43M | 1.68M | 1.84M | 345.74M | 854,000 | 1.13M | 1.39M | 1.64M | 1.87M | 2.10M |
| Cash & Equiv | 130.89M | 134.93M | 116.81M | 108.64M | 153.99M | 154.08M | 133.02M | 105.40M | 114.61M | 295.39M | 94.55M | 97.28M |
| Book Value | 41.62M | 64.63M | 115.43M | 157.42M | 215.06M | 288.12M | 366.43M | 434.34M | 491.89M | 554.20M | 359.19M | 400.04M |
| Return on Equity | -1.03 | -1.05 | -0.53 | -0.46 | -0.39 | -0.33 | -0.23 | -0.16 | -0.15 | -0.13 | -0.14 | -0.11 |
